{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:23:06Z","timestamp":1782786186931,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T00:00:00Z","timestamp":1577059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The International Prognostic Score (IPS) is the most commonly used risk stratification tool for patients with advanced Hodgkin lymphoma (HL). It incorporates seven clinical parameters independently associated with a poorer outcome: male sex, age, stage IV, hemoglobin level, white blood cell and lymphocyte counts, and albumin level. Since the development of the IPS, there have been significant advances in therapy and supportive care. Recent studies suggest that the IPS is less discriminating due to improved outcomes with ABVD therapy. The aim of the present study was to asses if classic prognostic factors maintain their prognostic meaning at the time of response-adapted treatment based on interim PET scans. We evaluated the prognostic significance of IPS in the 520 advanced stage HL patients enrolled in the PET-guided, HD0801 trial in which PET2-positive patients underwent a more intense treatment with an early stem-cell transplantation after 2 cycles of ABVD. We observed that in these patients, the IPS completely loses its prognostic value together with all the single parameters that contribute to the IPS. Furthermore, neutrophils, monocytes, lymphocytes, and the ratio among them also no longer had any predictive value. We believe that the substantial improvement in survival outcomes in PET2-positive patients treated with early autologous transplantation could explain the complete disappearance of the residual prognostic significance of the IPS.<\/jats:p>","DOI":"10.1007\/s00277-019-03893-7","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T10:03:25Z","timestamp":1577095405000},"page":"277-282","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["The classic prognostic factors in advanced Hodgkin\u2019s lymphoma patients are losing their meaning at the time of Pet-guided treatments"],"prefix":"10.1007","volume":"99","author":[{"name":"Fondazione Italiana Linfomi (Onlus)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Bari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Marcheselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Botto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Lia","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Puccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Pulsoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Santoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Nassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Meli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Pavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Bonfichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Evangelista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Gioia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Levis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Zinzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,23]]},"reference":[{"key":"3893_CR1","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1056\/NEJM199811193392104","volume":"339","author":"D Hasenclever","year":"1998","unstructured":"Hasenclever D, Diehl A (1998) prognostic score for advanced Hodgkin\u2019s disease. International Prognostic Factors Project on Advanced Hodgkin\u2019s Disease. N Engl J Med 339:1506\u20131514","journal-title":"N Engl J Med"},{"key":"3893_CR2","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1200\/JCO.2011.41.0910","volume":"30","author":"AA Moccia","year":"2012","unstructured":"Moccia AA, Donaldson J, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Shenkier TN, Slack GW, Skinnider B, Gascoyne RD, Connors JM, Sehn LH (2012) International Prognostic Score in advanced-stage Hodgkin\u2019s lymphoma: altered utility in the modern era. J Clin Oncol 30:3383\u20133388","journal-title":"J Clin Oncol"},{"key":"3893_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1111\/bjh.13634","volume":"171","author":"CS Diefenbach","year":"2015","unstructured":"Diefenbach CS, Li H, Hong F, Gordon LI et al (2015) Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era. Br J Haematol 171:530\u2013538","journal-title":"Br J Haematol"},{"key":"3893_CR4","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","volume":"31","author":"LI Gordon","year":"2013","unstructured":"Gordon LI, Hong F, Fisher RI, Bartlett NL et al (2013) Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). J Clin Oncol 31:684\u2013691","journal-title":"J Clin Oncol"},{"key":"3893_CR5","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1200\/JCO.2015.63.0699","volume":"34","author":"PL Zinzani","year":"2016","unstructured":"Zinzani PL, Broccoli A, Gioia DM, Castagnoli A, Ciccone G, Evangelista A, Santoro A, Ricardi U, Bonfichi M, Brusamolino E, Rossi G, Anastasia A, Zaja F, Vitolo U, Pavone V, Pulsoni A, Rigacci L, Gaidano G, Stelitano C, Salvi F, Rusconi C, Tani M, Freilone R, Pregno P, Borsatti E, Sacchetti GM, Argnani L, Levis A (2016) Interim positron emission tomography response-adapted therapy in advanced-stage Hodgkin lymphoma: final results of the phase II part of the HD0801 Study. J Clin Oncol 34:1376\u20131385","journal-title":"J Clin Oncol"},{"key":"3893_CR6","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1016\/j.mayocp.2015.03.025","volume":"90","author":"T Tadmor","year":"2015","unstructured":"Tadmor T, Bari A, Marcheselli L et al (2015) Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: evaluation based on data from 1450 patients. Mayo Clin Proc 90:756\u2013764","journal-title":"Mayo Clin Proc"},{"key":"3893_CR7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/hon.2359","volume":"35","author":"R Marcheselli","year":"2017","unstructured":"Marcheselli R, Bari A, Tadmor T, Marcheselli L, Cox MC, Pozzi S, Ferrari A, Baldini L, Gobbi P, Aviv A, Pugliese G, Federico M, Polliack A, Sacchi S (2017) Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: results of a large multicenter study involving 990 patients. Hematol Oncol 35:561\u2013566","journal-title":"Hematol Oncol"},{"key":"3893_CR8","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1200\/JCO.2015.63.1119","volume":"34","author":"OW Press","year":"2016","unstructured":"Press OW, Li H, Sch\u00f6der H, Straus DJ, Moskowitz CH, LeBlanc M, Rimsza LM, Bartlett NL, Evens AM, Mittra ES, LaCasce A, Sweetenham JW, Barr PM, Fanale MA, Knopp MV, Noy A, Hsi ED, Cook JR, Lechowicz MJ, Gascoyne RD, Leonard JP, Kahl BS, Cheson BD, Fisher RI, Friedberg JW (2016) Using early interim fluorodeoxyglucose-positron emission tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020\u20132027","journal-title":"J Clin Oncol"},{"key":"3893_CR9","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","volume":"23","author":"P Johnson","year":"2016","unstructured":"Johnson P, Federico M, Kirkwood A et al (2016) Adapted treatment guided by interim PET-CT scan in advanced Hodgkin\u2019s lymphoma. N Engl J Med 23:2419\u20132429","journal-title":"N Engl J Med"},{"key":"3893_CR10","first-page":"454","volume":"36","author":"A Gallamini","year":"2018","unstructured":"Gallamini A, Tarella C, Viviani S et al (2018) Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 Trial. Clin Oncol 36:454\u2013462","journal-title":"Clin Oncol"},{"key":"3893_CR11","doi-asserted-by":"crossref","unstructured":"Romano A, Parrinello NL, Vetro C et al (2018) Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy. Ann Hematol 97:1009\u20131018","DOI":"10.1007\/s00277-018-3276-y"},{"key":"3893_CR12","doi-asserted-by":"crossref","unstructured":"Agostinelli C, Gallamini A, Stracqualursi L et al (2016) The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin\u2019s lymphoma: a retrospective, European, multicentre cohort study. Lancet Haematol 10:e467\u2013e479","DOI":"10.1016\/S2352-3026(16)30108-9"},{"key":"3893_CR13","doi-asserted-by":"crossref","unstructured":"Steidl C, Lee T, Shah SP et al (2010) Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma. N Engl J Med 362:875\u2013885","DOI":"10.1056\/NEJMoa0905680"},{"key":"3893_CR14","doi-asserted-by":"crossref","unstructured":"Scott DW, Chan FC, Hong F et al (2013) Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma. J Clin Oncol 31:692\u2013700","DOI":"10.1200\/JCO.2012.43.4589"},{"key":"3893_CR15","doi-asserted-by":"crossref","unstructured":"Kanoun S, Rossi C, Berriolo-Riedinger A et al (2014) Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 41:1735\u20131743","DOI":"10.1007\/s00259-014-2783-x"},{"key":"3893_CR16","doi-asserted-by":"crossref","unstructured":"Pike LC, Kirkwood AA, Patrick P et al (2017) Can baseline pet-ct features predict outcomes in advanced Hodgkin lymphoma? A prospective evaluation of UK patients in RATHL trial (cruk \/07\/033). International Conference on Malignant Lymphoma Palazzo dei Congressi, Lugano (Switzerland), 14 \u2013 17 June, 2017. Hematol Oncol 35:37\u201338","DOI":"10.1002\/hon.2437_18"},{"key":"3893_CR17","doi-asserted-by":"crossref","unstructured":"Cottereau AS, Versari A, Loft A, Casasnovas O, Bellei M, Ricci R, Bardet S, Castagnoli A, Brice P, Raemaekers J, Deau B, Fortpied C, Raveloarivahy T, Van Zele E, Chartier L, Vander Borght T, Federico M, Hutchings M, Ricardi U, Andre M and Meignan M (2018) Prognostic value of baseline metabolic tumor volume in early\u2010stage hodgkin lymphoma in the standard arm of the H10 trial. Blood 131:1456\u20131463","DOI":"10.1182\/blood-2017-07-795476"},{"key":"3893_CR18","doi-asserted-by":"crossref","unstructured":"Donati B, Casali M, Fama A et Al. A gene expression-based score to predict interim PET positivity in Hodgkin lymphoma patients treated with ABVD. IHCL 2019 Abstract book n. 17: p48","DOI":"10.1002\/hon.17_2629"}],"updated-by":[{"DOI":"10.1007\/s00277-020-04344-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,11,21]],"date-time":"2020-11-21T00:00:00Z","timestamp":1605916800000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03893-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-019-03893-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-019-03893-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,4]],"date-time":"2021-01-04T08:10:32Z","timestamp":1609747832000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-019-03893-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,23]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["3893"],"URL":"https:\/\/doi.org\/10.1007\/s00277-019-03893-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00277-020-04344-4","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,23]]},"assertion":[{"value":"8 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the article entitled \ufffd\ufffd\ufffdThe classic prognostic factors in advanced Hodgkin\ufffd\ufffd\ufffds lymphoma patients are losing their meaning at the time of Pet-guided treatments\ufffd\ufffd\ufffd, the affiliation of Armando Santoro should be corrected as follows:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All local ethic committees at each center approved the study protocol and its amendments in accordance with Italian law and in compliance with the Declaration of Helsinki. Patients provided written informed consent before being included in the study.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors declare that they have no conflict of interest","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}